Discover how Flow can transform your Clinic
56% remission rate and real time ability to adapt treatment plans.
Trusted by hundreds of clinicians who use Flow’s Clinical Patient Platform for remote monitoring with better outcomes.
Discover how Flow can transform your Clinic
56% remission rate and real time ability to adapt treatment plans.
Trusted by hundreds of clinicians who use Flow’s Clinical Patient Platform for remote monitoring with better outcomes.
Used by the NHS
Trusted by 12,000 users
Used in over 100 Clinics
Drug-free wearable headset
75%12 of patients want a drug-free depression treatment. Over 1.4 million in the UK alone are waiting to see a therapist13.
Flow is the first clinically-validated platform that delivers an effective1, drug-free depression treatment that directly targets the physical causes of depression from the comfort of patient homes.
Combining a safe, easy-to-use brain stimulation wearable with a guided app program and clinician remote monitoring portal, Flow’s engineers and clinicians have created a measurable alternative
depression treatment.
Half of patients in remission at 10 weeks
Remission rates in our clinical trial show 56% are depression-free at 10 weeks3.
Within a few weeks, the Flow treatment is associated with supporting improvements in mood, concentration, optimism and initiative, while reducing anxiety and suicidal thoughts2.
Full clinical trial results will be released in Autumn 2023.
Efficacy on par with antidepressants and TMS across studies
Our latest clinical trial shows that Flow is twice as effective as antidepressants. Using an odds ratio to measure the difference in effect between treatment and placebo, Flow has an odds ratio of 3.113 Vs Antidepressants at 1.684.
Other clinical studies show that tDCS is as effective as antidepressants as well as TMS5-6.
Our first clinical trial shows remission rates of 56% after 10 weeks3 while clinical trials reviewing antidepressants show a remission rate of 40%7-8.
No major side effects
For the majority taking antidepressants, side effects are inevitable9. Studies show that antidepressants often impact libido, appetite and energy levels10.
Depression treatment can be side effect free. tDCS longitudinal studies report no major adverse events11. Flow’s real-world data also shows less than 2% (from 7500+ patients) reporting minor side effects such as headaches and skin irritation2.
Approved for at-home use across the UK and EU
FDA breakthrough device designation for at-home depression treatment
Approved by the British Standards Institution (BSI)
Class IIa medical device CE-marked. Approved for use in the EU and UK
Tested according to IEC 60601 for electrical medical device safety
Flow in practice
7,500+ users with a 60% adherence rate across the board2
50+ clinics in the UK and EU formally offering Flow
Multiple NHS pilots from primary care setting to TMS specialists
Introducing our scientific advisory board
André Russowsky Brunoni, MD, PhD
Associate Professor at the Faculty of Medicine, University of São Paulo
Andrew A. Nierenberg, MD, PhD
Professor of Psychiatry, Harvard Medical School
Allan H. Young, MB, PhD
Professor of Psychiatry, King’s College London
Joan Camprodon-Gimenez, MD, PhD, MPH
Associate Professor of Psychiatry, Harvard Medical School
Corey Keller, MD, PhD
Assistant Professor of Psychiatry and Behavioral Sciences, Stanford University
Clinics currently using Flow
Having been used to offering rTMS to patients as a last resort, it is very liberating to be able to offer Flow as one of several initial treatment choices. Patients find it very easy to use and I love the fact that I can monitor their use using a validated scale.
Phoenix Mental Health Services, UK
We have found Flow incredibly useful for supporting clients... The clinician interface is very user friendly and allows us access to monitor client progress remotely without the need for multiple phone-calls.
BrainState, UK
At E.Stim we have been using Flow tDCS devices and corresponding app-based therapy solution to improve mood and reduce symptoms of depression in adult patients. The clinician dashboard features help clinicians to tailor their patients' treatment plans to achieve optimal outcomes.
E.Stim, Portugal
Flow in the media
References
1. Fu Cynthia H.Y., et al. J Psychiatric Research. 2022;153:197-205.
2. Data on File.
3. Double-blinded, placebo-controlled clinical trial (n=173) to measure the effectiveness and safety of Flow’s at-home tDCS depression treatment (2023). Trial took place at University of Texas and the University of East London. PI: Cynthia Fu (Honorary Consultant Psychiatrist at the South London and Maudsley NHS Foundation Trust). Summary of protocol: Link
4. Cipriani, Furukawa, Salanti et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with MDD: meta-analysis. 2018. Link.
5. Mutz J, et al. BMJ. 2019;364:l1079.
6. Brunoni AR, et al. JAMA Psychiatry. 2013;70(4):383-91.
7. Machado M, et al. Current medical research and opinion. 2006;22(9),1825–1837.
8. Thase ME, et al. J Clin Psychiatry. 2005;66(8), 974–981.
9. Read J, Williams J. Curr Drug Saf. 2018;13(3):176-186.
10. Carvalho AF, et al. Psychother Psychosom.
11. Chhabra Harleen et al. Psychiatry Res; 284, 2020.
12. McHugh RK, et al. J Clin Psychiatry. 2013;74(6):595-602.
13. Outpatient Mental Health Access and Workforce Crisis Issue Brief. Association for Behavioral Healthcare. 2022.